During a meeting with investors in May, Lupin executives said they are developing both injectable and tablet forms of semaglutide for sale in India and South Africa in 2026
The SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20 percent in overweight and obese adults with established cardiovascular disease
from excess weight, by reducing overall fat burden and improving metabolism, your body may regain movement and reduce pain
Appetite suppression can make it harder to eat enough protein and micronutrients
These medications can sometimes trigger dry mouth, acid reflux, tooth sensitivity, and even enamel wear
Psychiatric comorbidity in 36 adults with mitochondrial cytopathies